secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001411685-24-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen Q1 FY2025 net loss $10.7M; PALISADE Phase 3 trials on track for 2025 results
--------------------------------------------------------------------------------

- Net loss of $10.7M for Q1 FY2025, up from $6.9M in Q1 FY2024.
- Cash, cash equivalents, and marketable securities at $108.4M as of June 30, 2024.
- PALISADE-3 Phase 3 trial for fasedienol in SAD on track for top-line results in 2025.
- PALISADE-4 Phase 3 trial preparation ongoing; initiation planned H2 2024.
- R&D expenses increased to $7.6M from $4.2M due to PALISADE trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000039/0001411685-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000039/vtgn-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001411685-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer